{
  "personality": null,
  "timestamp": "2025-09-17T04:35:17.611767",
  "category": "Health",
  "news_summary": "Advancements in medical research show promising treatments for fatty liver disease and dengue virus, innovative approaches to managing appetite, and new methods to predict mental health risks in children.",
  "news_summary_fr": "Les progrès de la recherche médicale montrent des traitements prometteurs pour la stéatose hépatique et le virus de la dengue, des approches innovantes pour gérer l'appétit et de nouvelles méthodes pour prédire les risques de santé mentale chez les enfants.",
  "news_summary_es": "Los avances de la investigación médica muestran tratamientos prometedores para la enfermedad del hígado graso y el virus del dengue, enfoques innovadores para controlar el apetito y nuevos métodos para predecir los riesgos de salud mental en los niños.",
  "articles": [
    {
      "title": "New drug could be first to stop deadly fatty liver disease",
      "summary": "Scientists at UC San Diego have identified a new drug, ION224, that could transform the treatment of MASH, a dangerous form of fatty liver disease tied to obesity and diabetes. By blocking a key liver enzyme, the drug reduces fat and inflammation, halting the root causes of liver damage. In a year-long clinical trial, patients showed major improvements without serious side effects, offering hope to millions affected worldwide.",
      "content": "Researchers at University of California San Diego School of Medicine have identified a new investigational drug that shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease linked to obesity and type 2 diabetes that can lead to cirrhosis, liver failure, and even liver cancer.\n\nThe study, published in the August 23, 2025 online edition of The Lancet, found that the medication, ION224, targets a liver enzyme called DGAT2, which plays a key role in how the liver produces and stores fat. By blocking this enzyme, the drug helps reduce fat buildup and inflammation, two major drivers of liver damage in MASH.\n\n\"This study marks a pivotal advance in the fight against MASH,\" said Rohit Loomba, MD, principal investigator of the study and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. \"By blocking DGAT2, we're interrupting the disease process at its root cause, stopping fat accumulation and inflammation right in the liver.\"\n\nThe multicenter, Phase IIb clinical trial involved 160 adults with MASH and early to moderate fibrosis across the United States. Participants received monthly injections of the drug at different doses or a placebo over the course of one year. At the highest dose, 60% showed notable improvements in their liver health compared to the placebo group. These benefits occurred regardless of weight change, suggesting the drug could be used alongside other therapies. The medicine showed no serious side effects linked to the treatment.\n\nMASH, formally known as nonalcoholic steatohepatitis (NASH), affects people with metabolic conditions like obesity and type 2 diabetes. It is often called a \"silent\" disease because it can progress for years without symptoms.\n\nMore than 100 million people have some form of fatty liver disease in the U.S. and as many as 1 in 4 adults worldwide may be affected, according to the Centers for Disease Control and Prevention. If left untreated, MASH can progress to liver failure and often may require a transplant.\n\n\"This is the first drug of its kind to show real biological impact in MASH,\" Loomba said. \"If these findings are confirmed in Phase III trials, we may finally be able to offer patients a targeted therapy that halts and potentially reverses liver damage before it progresses to life-threatening stages.\"\n\nLoomba, who is also director of the metabolic-dysfunction associated steatotic liver disease (MASLD) research center at UC San Diego School of Medicine, and a gastroenterologist and hepatologist at UC San Diego Health, adds that for patients and families affected by this serious condition, these results bring new hope for better care and outcomes. He emphasizes that early intervention and targeted therapies may also help reduce the burden on health care systems by preventing costly and complex liver disease down the line.\n\nNext steps include a larger clinical trial to move closer to making this treatment widely available.\n\nCo-authors of the study include Erin Morgan, Keyvan Yousefi, Dan Li, Richard Geary, Sanjay Bhanot, all from Ionis Pharmaceuticals, and Naim Alkhouri, Arizona Liver Health.\n\nFunding for this research came from Ionis Pharmaceuticals (ION224-CS2).",
      "url": "https://www.sciencedaily.com/releases/2025/09/250915202836.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-09-16",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant medical breakthrough with a new drug, ION224, that effectively treats a serious and widespread liver disease (MASH) linked to obesity and diabetes. The drug demonstrated clear clinical benefits in a well-defined trial, offering hope to millions globally, which constitutes a meaningful positive impact on public health.",
      "category": "Health",
      "personality_title": "New drug ION224 shows promise in treating serious fatty liver disease",
      "personality_presentation": "**Context** – Metabolic dysfunction-associated steatohepatitis (MASH) is a dangerous type of fatty liver disease linked to obesity and type 2 diabetes. It can cause severe liver damage, including liver failure and cancer, and often shows no symptoms until it is advanced. Over 100 million people in the U.S. and millions worldwide are affected.\n\n**What happened** – Scientists at the University of California San Diego tested a new drug called ION224 in a year-long clinical trial involving 160 adults with MASH. The drug works by blocking an enzyme in the liver named DGAT2, which helps reduce fat buildup and inflammation, two main causes of liver damage. Patients who received the highest dose of ION224 showed significant liver improvements compared to those who got a placebo, with no serious side effects.\n\n**Impact** – This is the first drug to directly target the root cause of MASH by stopping fat and inflammation in the liver. Its success in the trial offers a new way to treat a disease that currently has no approved medicines. Because the drug worked regardless of weight loss, it could help many patients alongside other treatments, potentially preventing the need for liver transplants.\n\n**What's next step** – Researchers plan to conduct larger Phase III trials to confirm these results and work toward making ION224 available to patients. If successful, this drug could become the first approved treatment to halt or even reverse liver damage caused by MASH.\n\n**One-sentence takeaway** – A new drug, ION224, has shown real promise in safely reducing liver fat and inflammation, offering hope for effective treatment of a common and serious liver disease linked to obesity and diabetes.",
      "personality_title_fr": "Le nouveau médicament ION224 montre des résultats prometteurs contre une maladie grave du foie gras",
      "personality_presentation_fr": "**Contexte** – La stéatohépatite métabolique associée (MASH) est une forme dangereuse de maladie du foie gras liée à l’obésité et au diabète de type 2. Elle peut causer de graves lésions hépatiques, y compris une insuffisance hépatique et un cancer, souvent sans symptômes au début. Plus de 100 millions de personnes aux États-Unis et des millions dans le monde en sont touchées.\n\n**Ce qui s’est passé** – Des scientifiques de l’Université de Californie à San Diego ont testé un nouveau médicament appelé ION224 lors d’un essai clinique d’un an avec 160 adultes atteints de MASH. Ce médicament bloque une enzyme du foie nommée DGAT2, ce qui réduit l’accumulation de graisse et l’inflammation, deux causes principales des dommages au foie. Les patients ayant reçu la dose la plus élevée ont montré une amélioration significative de leur foie, sans effets secondaires graves.\n\n**Impact** – C’est le premier médicament qui cible directement la cause racine de la MASH en arrêtant la graisse et l’inflammation dans le foie. Son succès lors de l’essai offre une nouvelle option pour traiter une maladie sans traitement approuvé. Le médicament ayant fonctionné même sans perte de poids, il pourrait aider beaucoup de patients en complément d’autres thérapies, évitant parfois une transplantation du foie.\n\n**Prochaine étape** – Les chercheurs prévoient des essais plus larges de phase III pour confirmer ces résultats et permettre la mise à disposition d’ION224 aux patients. Si cela réussit, ce médicament pourrait devenir le premier traitement approuvé capable d’arrêter ou même d’inverser les lésions du foie causées par la MASH.\n\n**Une phrase clé** – Le nouveau médicament ION224 a montré une réelle efficacité pour réduire la graisse et l’inflammation du foie en toute sécurité, offrant une nouvelle voie pour traiter une maladie courante et grave liée à l’obésité et au diabète.",
      "personality_title_es": "Nuevo medicamento ION224 muestra avances en el tratamiento de grave enfermedad del hígado graso",
      "personality_presentation_es": "**Contexto** – La esteatohepatitis asociada a disfunción metabólica (MASH) es una forma peligrosa de enfermedad del hígado graso vinculada a la obesidad y la diabetes tipo 2. Puede causar daño grave al hígado, incluyendo insuficiencia hepática y cáncer, y a menudo no presenta síntomas al principio. Más de 100 millones de personas en EE.UU. y millones en todo el mundo están afectadas.\n\n**Qué pasó** – Científicos de la Universidad de California en San Diego probaron un nuevo medicamento llamado ION224 en un ensayo clínico de un año con 160 adultos con MASH. El medicamento bloquea una enzima del hígado llamada DGAT2, lo que reduce la acumulación de grasa y la inflamación, principales causas de daño hepático. Los pacientes que recibieron la dosis más alta mostraron mejoras significativas en el hígado, sin efectos secundarios graves.\n\n**Impacto** – Es el primer medicamento que ataca directamente la causa principal de la MASH al detener la grasa y la inflamación en el hígado. Su éxito en el ensayo ofrece una nueva opción para tratar una enfermedad que no tiene tratamientos aprobados. Como funcionó sin importar la pérdida de peso, podría ayudar a muchos pacientes junto con otras terapias, evitando trasplantes de hígado.\n\n**Próximo paso** – Los investigadores planean realizar ensayos más grandes de fase III para confirmar estos resultados y avanzar hacia la disponibilidad de ION224 para los pacientes. Si tiene éxito, podría ser el primer tratamiento aprobado para detener o revertir el daño hepático causado por la MASH.\n\n**Una frase clave** – El nuevo medicamento ION224 ha demostrado ser eficaz y seguro para reducir la grasa y la inflamación en el hígado, ofreciendo esperanza para tratar una enfermedad común y grave relacionada con la obesidad y la diabetes.",
      "image_url": "public/images/news_image_New-drug-could-be-first-to-stop-deadly-fatty-liver.png",
      "image_prompt": "A warm, detailed painting of a healthy golden liver gently cradled by two stylized hands glowing with soft light, surrounded by subtle abstract shapes representing blocked fat deposits dissolving away, set against a calm background of natural earth tones symbolizing healing and hope."
    },
    {
      "title": "How billions of hacked mosquitoes and a vaccine could beat the deadly dengue virus",
      "summary": "Nature, Published online: 16 September 2025; doi:10.1038/d41586-025-02918-8Outbreaks of dengue are killing thousands of people in South America each year and getting worse. Brazil hopes to turn the tide with a home-grown vaccine and an army of mosquitoes infected with Wolbachia bacteria.",
      "content": "Support for this article was provided by the Pulitzer Center.\n\nLast month, a parade of vehicles wound its way through three cities in Brazil, releasing clouds of mosquitoes into the air. The insects all carry a secret weapon — a bacterium called Wolbachia that lowers the odds that the mosquitoes can transmit the dreaded dengue virus to humans.\n\nThis is the world’s largest ‘mosquito factory’: its goal is to stop dengue\n\nThese infected mosquitoes are the latest weapon in Brazil’s fight against dengue, which infects millions of people in the country each year and can be fatal. A biofactory that opened in the town of Curitiba in July can produce 100 million mosquito eggs per week — making it the largest such facility in the world. The company that runs it, Wolbito do Brasil, aims to protect about 14 million Brazilians per year through its Wolbachia-infected mosquitoes.\n\nThat will come as welcome news for the Brazilian health officials battling the rapidly growing threat of dengue. In 2024, the country experienced its worst outbreak yet: with 6.6 million probable cases and more than 6,300 related deaths. This year’s outbreak, although less severe, is also one of the highest on record, with 1.6 million probable cases so far (see ‘Dangerous outbreaks’). And the problem is spreading. Argentina, Colombia and Peru also experienced record-breaking outbreaks in 2024 and have seen a sustained increase in cases in recent years. Across Latin America and the Caribbean, deaths from dengue last year totalled more than 8,400 and the global figure reached more than 12,000 — the highest ever recorded for this disease.\n\nSOURCE: Brazilian Ministry of Health\n\nAs outbreaks grow larger and the crisis becomes more urgent, the Wolbachia method isn’t Brazil’s only bet. A locally produced dengue vaccine is now awaiting approval by the country’s drug-regulatory agency, and its health ministry expects to start administering tens of millions of doses by next year.\n\nThese twin advances offer some hope to other countries — in the region and beyond. Driven by forces such as climate change, mosquito adaptation, globalized trade and movements of people, dengue is becoming a crisis worldwide, with an estimated 3.9 billion people at risk of infection. As Brazil rolls out its armies of infected mosquitoes and a vaccine in the coming year, the rest of the world will be watching closely.\n\nThe local approach\n\nCurrently, there is one main dengue vaccine in use around the world: Qdenga, licensed by the Japanese pharmaceutical company Takeda. The vaccine has been approved in many countries, including Brazil, which was the first nation to include it in its public-health system.\n\nHowever, Qdenga’s roll-out in Brazil is limited. The country bought nine million doses of the two-dose vaccine this year: enough to vaccinate 4.5 million of its population of more than 210 million. So far, Qdenga has been administered to children between the ages of 10 and 14, one of the groups most likely to end up in hospital after contracting dengue, together with older people. Its safety and efficacy have not yet been tested in adults aged over 60.\n\nThe main reasons for such a limited roll-out in Brazil are availability and cost. Even though Brazil secured Qdenga from Takeda at one of the cheapest prices in the world —around US$19 per dose — the cost is still high compared with other vaccines. And even in the most optimistic scenario, the maximum number of doses Takeda could provide by 2028 is 50 million — enough to vaccinate 25 million people. What’s more, for people who have not had dengue before, clinical trials did not show Qdenga to be effective against all four variants — or serotypes — of the dengue virus.\n\nWhen will dengue strike? Outbreaks sync with heat and rain\n\nBrazil is trying to address all of those limitations with its one-dose vaccine candidate, developed at the Butantan Institute, a public biomedical research centre in São Paulo. “Having local production capacity gives us independence on decisions — how many doses we need, and at what speed to vaccinate,” says Esper Kallás, Butantan’s director. “You can practise prices that are more suitable and absorbable by a public-health system such as Brazil’s.”\n\nButantan is also optimistic that its vaccine will be effective against all four forms of dengue. Severe disease usually occurs when a person is infected by a different serotype to their first infection. That means that a successful vaccine needs to generate antibodies for all four serotypes without triggering severe reactions, which makes it a difficult vaccine to develop. “It was indeed a challenge, as each serotype behaves differently,” says Neuza Frazatti Gallina, manager of the viral vaccine development laboratory at Butantan.\n\nThe vaccine’s development began at the US National Institutes of Health in the late 1990s, where scientists transformed dengue viruses they had isolated from patients into weakened vaccine strains that could trigger the production of protective antibodies without causing disease. In 2009, Butantan extended that research by working to solve the challenges of combining the four strains into a vaccine.\n\nEggs of mosquitoes infected with Wolbachia bacteria. After hatching, the mosquitoes will be released to prevent the spread of dengue.Credit: Xinhua/Shutterstock\n\nAfter testing 30 formulations, Butantan arrived at one that proved highly effective in preventing infections, according to the preliminary results of a phase III trial involving more than 16,000 volunteers in Brazil. The study reported that two years after vaccinations, the formulation was 89% effective in preventing infections in people who had previously been infected with dengue, and 74% effective in those with no previous exposure1.\n\n“It was a well-designed trial,” says Annelies Wilder-Smith, who is team lead for vaccine development at the World Health Organization (WHO). But she says one limitation of the trial is that it was conducted in a single country, and therefore runs a risk that all four serotypes were not circulating at the time.\n\nIn fact, serotypes 3 and 4 were not prevalent during the data-collection period of the clinical trial, although they are now circulating in Brazil. Butantan researchers suggest that the vaccine will be effective against serotypes 3 and 4, pointing to data from a phase II trial2 in 300 adults that showed participants produced neutralizing antibodies to each of the serotypes. That study evaluated safety and immunological response in the short term, rather than looking at the vaccine’s long-term efficacy in preventing infections. The full results of the Brazilian phase III trial — which will provide data on long-term effectiveness — are not yet public and are undergoing peer review.\n\nThe vaccine is already moving through the country’s regulatory process. And although there’s still no certainty about when Anvisa, Brazil’s regulatory agency, will approve the vaccine, the government is counting on it. In February, President Luiz Inácio Lula da Silva announced that, starting in 2026, the Ministry of Health would be buying 60 million doses annually.\n\nTo meet that demand, Butantan is now producing the vaccine at its São Paulo facility. On its lush campus, an entire building is dedicated to churning out doses.\n\nRegarding the vaccine’s approval, “We are very confident,” says Kallás. “We also anticipate that there is a very prominent need to have this product in the arms of people. So we hit the road running and started producing vaccines late last year.”\n\nAlthough Butantan’s production efforts will focus initially on meeting Brazil’s need for millions of doses, Kallás expects that the vaccine could reach other countries. Butantan has been discussing with its development partner — the pharmaceutical giant Merck — and the Pan American Health Organization (PAHO) how to make the vaccine accessible to other countries. The logical first step, he says, would be to roll it out through PAHO to Latin America and the Caribbean, and then to other regions.\n\nIn the meantime, Merck is developing a potential vaccine for Asia with an almost identical formulation, which builds on the knowledge that Butantan has developed. In a statement, the drug firm said that Butantan is “sharing clinical data and other learnings”. In June, Merck started enrolling participants for its own phase III trial. “All the data, experiences and insights they have collected with the Butantan vaccine will be helpful,” says Wilder-Smith.\n\nInfecting mosquitoes\n\nWhile Butantan awaits news about the vaccine’s approval, the Wolbachia method to control dengue is gaining momentum. The World Mosquito Program (WMP) — a non-profit group of companies owned by Monash University in Melbourne, Australia, where the strategy was developed — has operations in 14 countries, including Vietnam, Indonesia, Mexico and Colombia, but Brazil leads the way in terms of the scale of its expansion.\n\nThe method’s arrival in the Americas is tied to Brazilian researcher Luciano Moreira, now the chief executive of Wolbito do Brazil. Wolbachia is naturally present in around 50% of insects, but not in the mosquito species Aedes aegypti, which is the main transmitter of dengue and many other viruses.",
      "url": "https://www.nature.com/articles/d41586-025-02918-8",
      "source": "Nature",
      "published": "2025-09-17",
      "sentiment_score": 0.9,
      "reasoning": "The article reports on Brazil's large-scale, innovative efforts to combat dengue fever through a combination of releasing Wolbachia-infected mosquitoes and developing a locally produced vaccine. These measures have the potential to significantly reduce dengue infections and deaths, benefiting millions in Brazil and potentially other countries. The story is detailed, focused, and highlights a major public health advancement with broad societal impact.",
      "category": "Health",
      "personality_title": "Brazil launches large-scale mosquito and vaccine efforts to fight dengue fever",
      "personality_presentation": "**Context** – Dengue fever is a serious illness spread by mosquitoes, causing millions of infections and thousands of deaths every year in South America. Brazil has faced some of the worst outbreaks, with millions falling ill and thousands dying recently.\n\n**What happened** – Brazil has started releasing billions of mosquitoes infected with a special bacterium called Wolbachia. This bacterium stops mosquitoes from spreading dengue. At the same time, Brazil is developing its own dengue vaccine to protect people from all four types of the virus. A huge new factory in Curitiba produces 100 million mosquito eggs weekly, and the vaccine is nearing approval to be given to millions.\n\n**Impact** – These two new tools work together to fight dengue in ways not done before. The Wolbachia mosquitoes reduce the chances of infection by blocking virus spread, while the vaccine aims to protect people from all forms of dengue, including those who have never had it. This combined approach could lower the number of infections and deaths significantly in Brazil and nearby countries.\n\n**What’s next step** – Brazil plans to start giving the new vaccine widely in 2026 and continue releasing infected mosquitoes. The vaccine might also be shared with other countries in Latin America and beyond. Meanwhile, scientists will keep monitoring how well these methods work and improve them if needed.\n\n**One-sentence takeaway** – Brazil is using millions of Wolbachia-infected mosquitoes and a new vaccine to reduce dengue fever and protect millions of people from this dangerous disease.\n",
      "personality_title_fr": "Le Brésil déploie des moustiques modifiés et un vaccin pour lutter contre la dengue",
      "personality_presentation_fr": "**Contexte** – La dengue est une maladie grave transmise par les moustiques, causant des millions d’infections et des milliers de décès chaque année en Amérique du Sud. Le Brésil a connu certaines des pires épidémies récemment.\n\n**Ce qui s’est passé** – Le Brésil a commencé à relâcher des milliards de moustiques infectés par une bactérie spéciale appelée Wolbachia. Cette bactérie empêche les moustiques de transmettre la dengue. En même temps, le pays développe son propre vaccin contre la dengue, capable de protéger contre les quatre types du virus. Une grande usine à Curitiba produit 100 millions d’œufs de moustiques chaque semaine, et le vaccin est sur le point d’être approuvé.\n\n**Impact** – Ces deux nouvelles méthodes combinées offrent une lutte inédite contre la dengue. Les moustiques porteurs de Wolbachia réduisent la transmission du virus, tandis que le vaccin protège contre toutes les formes de la maladie, même chez ceux qui n’ont jamais été infectés. Cela pourrait réduire fortement le nombre de malades et de décès au Brésil et dans les pays voisins.\n\n**Prochaine étape** – Le Brésil prévoit de commencer la vaccination à grande échelle en 2026 et de continuer à relâcher les moustiques infectés. Le vaccin pourrait aussi être distribué à d’autres pays d’Amérique latine et au-delà. Les chercheurs suivront l’efficacité de ces actions pour les améliorer.\n\n**Phrase clé** – Le Brésil utilise des millions de moustiques porteurs de Wolbachia et un nouveau vaccin pour réduire la dengue et protéger des millions de personnes.\n",
      "personality_title_es": "Brasil lanza esfuerzo masivo de mosquitos modificados y vacuna para combatir el dengue",
      "personality_presentation_es": "**Contexto** – El dengue es una enfermedad grave transmitida por mosquitos que causa millones de infecciones y miles de muertes cada año en Sudamérica. Brasil ha enfrentado algunos de los brotes más severos recientemente.\n\n**Qué pasó** – Brasil comenzó a liberar miles de millones de mosquitos infectados con una bacteria llamada Wolbachia, que evita que los mosquitos transmitan el dengue. Al mismo tiempo, está desarrollando una vacuna propia contra el dengue que protege contra los cuatro tipos del virus. Una gran fábrica en Curitiba produce 100 millones de huevos de mosquitos por semana y la vacuna está cerca de ser aprobada.\n\n**Impacto** – Estas dos herramientas nuevas trabajan juntas para combatir el dengue de forma innovadora. Los mosquitos con Wolbachia reducen la transmisión del virus, mientras que la vacuna busca proteger a las personas de todas las formas de la enfermedad, incluso a quienes nunca la han tenido. Esto podría disminuir mucho las infecciones y muertes en Brasil y países cercanos.\n\n**Próximo paso** – Brasil planea comenzar a aplicar la nueva vacuna en 2026 y continuar liberando los mosquitos infectados. La vacuna también podría llegar a otros países de América Latina y más allá. Los científicos seguirán evaluando la efectividad para mejorar estas estrategias.\n\n**Frase clave** – Brasil usa millones de mosquitos infectados con Wolbachia y una nueva vacuna para reducir el dengue y proteger a millones de personas.\n",
      "image_url": "public/images/news_image_How-billions-of-hacked-mosquitoes-and-a-vaccine-co.png",
      "image_prompt": "A detailed, warm painting of a swarm of stylized Aedes aegypti mosquitoes gently glowing with soft green hues to symbolize Wolbachia infection, flying over a vibrant Brazilian cityscape at dawn, with a subtle abstract representation of a protective shield formed by interlocking vaccine-shaped patterns enveloping the scene."
    },
    {
      "title": "Semaglutide may silence the food noise in your head",
      "summary": "People taking semaglutide report far fewer obsessive thoughts about food, with cravings dropping sharply and mental health improving. This new research hints the drug may offer freedom from the constant distraction of food noise.",
      "content": "New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (September 15-19) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.\n\nFood noise refers to obsessive and intrusive thoughts about food and eating. This preoccupation with food can hinder healthy lifestyle implementation and lead to overeating, making weight loss difficult.\n\nPrevious research has found that 57% of people who have living with overweight or obesity have experienced food noise, although few are familiar with the term. Many of those affected said that food noise made it more difficult to make healthy food choices or stick to an exercise plan.\n\nSome people also report that food noise affects their quality of life and their well-being.\n\nGlucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (brand names Wegovy and Ozempic) are highly effective at helping people who are living with obesity lose weight. By mimicking the action of a hormone called GLP-1, they reduce appetite and feelings of hunger, slow the release of food from the stomach and increase feelings of fullness after eating.\n\nHowever, little is known about how semaglutide, which was developed by Danish pharmaceutical company Novo Nordisk A/S, affects food noise.\n\nTo find out more, researchers from Novo Nordisk and Market Track LLC, a market research company, conducted a survey of 550 people in the US (average age 53 years, 86% female) who were taking semaglutide for weight loss.\n\nSome 81% (447) of the participants said they had been taking semaglutide for at least four months and 86% of the participants reported weighing at least 92kg (14st 7lb) before starting treatment.\n\nThe participants were asked how food noise was currently affecting them and to recall how it had affected them before starting treatment.\n\nAnalysis of the results showed that the participants were experiencing less food noise than before.\n\nThe proportion of participants experiencing constant thoughts about food throughout the day fell almost four-fold from 62% before starting treatment to 16%. The proportion who said they spent too much time thinking about food fell by a similar amount, from 63% to 15%.\n\nThe proportion who said they had uncontrollable thoughts about food fell more than three-fold from 53% to 15%; the proportion who said their thoughts about food had negative effects on them or their life fell from 60% to 20%; and the proportion who said their thoughts about food distracted them from completing everyday activities fell from 47% to 15%.\n\nThe survey also contained questions that covered several areas of mental well-being.\n\nHere, 352 (64%), 417 (76%) and 438 (80%) of the respondents reported an improvement in mental health, self-confidence and the development of healthier habits, respectively.\n\nIt is not known if these improvements were related to the drop in food noise or to the participants' weight loss.\n\nThe study's authors conclude that semaglutide may reduce the amount of food noise that is experienced by individuals who are living with obesity.",
      "url": "https://www.sciencedaily.com/releases/2025/09/250915202846.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-09-16",
      "sentiment_score": 0.85,
      "reasoning": "The article reports on new research showing that semaglutide, a drug used for weight loss, significantly reduces obsessive thoughts about food (food noise) and improves mental health and well-being for people living with obesity. This represents a meaningful health breakthrough with broad implications for improving quality of life and supporting weight management, supported by detailed survey data.",
      "category": "Health",
      "personality_title": "Semaglutide helps quiet constant food thoughts and improves well-being",
      "personality_presentation": "**Context** – Many people who struggle with obesity often experience 'food noise,' which means having constant, obsessive thoughts about food. This can make it hard to eat healthily or lose weight.\n\n**What happened** – Researchers surveyed 550 people in the US taking semaglutide, a medicine for weight loss. They found that after using the drug for at least four months, participants had far fewer constant or uncontrollable thoughts about food. For example, the number of people thinking about food all day dropped from 62% to 16%.\n\n**Impact** – This is important because food noise can distract people and harm their mental health. Along with fewer food thoughts, many participants said their mental health, self-confidence, and healthy habits improved. This shows semaglutide might help not just with weight loss but also with reducing the mental struggle around eating.\n\n**What's next step** – Scientists want to learn more about how semaglutide reduces food noise and whether these mental health benefits are directly caused by the drug or by losing weight. Future studies will explore this connection.\n\n**One-sentence takeaway** – Semaglutide may help people with obesity by lowering obsessive food thoughts and boosting mental well-being during weight loss.\n",
      "personality_title_fr": "Le sémaglutide aide à calmer les pensées constantes sur la nourriture et améliore le bien-être",
      "personality_presentation_fr": "**Contexte** – Beaucoup de personnes en surpoids ou obèses ont des pensées obsessionnelles sur la nourriture, appelées « bruit alimentaire ». Cela rend difficile le choix d’une alimentation saine ou la perte de poids.\n\n**Ce qui s’est passé** – Des chercheurs ont interrogé 550 personnes aux États-Unis prenant du sémaglutide, un médicament pour perdre du poids. Après au moins quatre mois de traitement, ils ont constaté que ces personnes pensaient beaucoup moins souvent à la nourriture. Par exemple, celles qui y pensaient toute la journée sont passées de 62 % à 16 %.\n\n**Impact** – Cela compte parce que ces pensées constantes peuvent gêner et nuire à la santé mentale. En plus de la baisse des pensées sur la nourriture, beaucoup ont dit se sentir mieux mentalement, plus confiants et avoir de meilleures habitudes. Le sémaglutide pourrait donc aider autant la perte de poids que la lutte mentale autour de l’alimentation.\n\n**Prochaine étape** – Les chercheurs veulent comprendre comment le sémaglutide réduit ce « bruit alimentaire » et si les bénéfices sur la santé mentale viennent du médicament ou de la perte de poids. De futures études vont approfondir ce lien.\n\n**Résumé en une phrase** – Le sémaglutide pourrait aider les personnes obèses en diminuant les pensées obsessionnelles sur la nourriture et en améliorant le bien-être mental pendant la perte de poids.\n",
      "personality_title_es": "El semaglutida ayuda a reducir los pensamientos constantes sobre la comida y mejora el bienestar",
      "personality_presentation_es": "**Contexto** – Muchas personas con sobrepeso u obesidad tienen pensamientos obsesivos sobre la comida, llamados «ruido alimentario». Esto dificulta tomar decisiones saludables y perder peso.\n\n**Qué pasó** – Investigadores encuestaron a 550 personas en Estados Unidos que tomaban semaglutida, un medicamento para bajar de peso. Después de al menos cuatro meses, notaron que pensaban mucho menos en la comida. Por ejemplo, quienes pensaban en comida todo el día bajaron del 62 % al 16 %.\n\n**Impacto** – Esto es importante porque estos pensamientos constantes pueden distraer y afectar la salud mental. Además de menos pensamientos sobre comida, muchos dijeron que mejoró su salud mental, confianza y hábitos saludables. Esto muestra que semaglutida podría ayudar no solo a perder peso, sino también a reducir la lucha mental con la comida.\n\n**Próximo paso** – Los científicos quieren saber cómo reduce el semaglutida el ruido alimentario y si los beneficios en salud mental vienen del medicamento o de la pérdida de peso. Estudios futuros investigarán esta relación.\n\n**Conclusión en una frase** – El semaglutida puede ayudar a personas con obesidad a reducir pensamientos obsesivos sobre la comida y mejorar su bienestar mental durante la pérdida de peso.\n",
      "image_url": "public/images/news_image_Semaglutide-may-silence-the-food-noise-in-your-hea.png",
      "image_prompt": "A warm, detailed painting of a calm human silhouette with a softly glowing brain area surrounded by gently fading, swirling thought bubbles shaped like various foods, symbolizing intrusive food thoughts quietly dissolving, set against a simple natural background of muted earth tones."
    },
    {
      "title": "Stress measured in hair could predict depression and anxiety in children",
      "summary": "Researchers from the University of Waterloo discovered that measuring long-term stress through children’s hair samples can reveal early signs of mental health risks in those living with chronic physical illnesses. Children with persistently high cortisol were more likely to struggle with anxiety, depression, and behavioral challenges, while those whose stress markers declined showed fewer problems.",
      "content": "Long-term stress levels, measured through hair samples, may provide important clues about mental health risks in children with chronic physical illnesses (CPI), according to new research from the University of Waterloo.\n\nThe study highlights how high hair cortisol, a type of steroid hormone, acts as a powerful early warning sign that could help identify children who live with CPI and who could be most at risk of mental health challenges, helping guide prevention and treatment strategies to better support their health and well-being.\n\nAn estimated 40 percent of children in Canada live with a CPI -- a number that has been rising steadily for decades. These children face a much higher risk of developing mental health problems than their healthy peers, putting them at greater risk for poor quality of life, suicidal thoughts and increased reliance on health-care services.\n\n\"Living with a chronic illness means facing daily challenges such as taking medications, missing school and adjusting activities, all of which can take a serious emotional toll,\" said Emma Littler, a Waterloo PhD candidate in Public Health Sciences and lead author of the study.\n\n\"Our findings suggest that chronically high stress, measured through hair samples, could help identify children with CPI at the highest risk for developing mental health problems. This opens the door to earlier and more targeted support.\"\n\nThe study followed 244 Canadian children with chronic physical illnesses over four years, measuring stress using hair cortisol -- a biological marker that reflects stress levels over time. Researchers found that more than two-thirds of these children had persistently high cortisol levels. Those children were also more likely to show symptoms of depression, anxiety, or other mental health concerns compared to peers whose cortisol levels decreased over time.\n\nWhen the researchers compared these patterns to reports of emotional and behavioral difficulties, they found that children whose cortisol levels declined over time showed fewer symptoms of anxiety, depression and behavior problems than those whose cortisol levels stayed high.\n\n\"Identifying these risk factors early could help doctors and families intervene before emotional and behavioral difficulties take hold,\" said Dr. Mark Ferro, a professor in Waterloo's School of Public Health Sciences and co-author of the study.\n\n\"Hair cortisol offers a non-invasive, easy-to-collect biomarker that could one day be used to screen children and track whether treatments or support programs are helping to reduce stress.\"\n\nThe study, \"Association between hair cortisol and psychopathology in children with a chronic physical illness,\" was recently published in Stress and Health.\n\nFerro and colleagues from Waterloo and McMaster University also published new research showing that biomarkers found in the blood of children with CPI may help predict future mental health challenges. The study, Inflammatory biomarkers predictive of psychopathology in children with physical illness, found that some blood signals were linked to children with CPI experiencing worsening mental health over time, while others were associated with improvements. The findings suggest that routine blood tests, combined with mental health check-ups, could help doctors identify children who may need extra support earlier.",
      "url": "https://www.sciencedaily.com/releases/2025/09/250915202834.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-09-16",
      "sentiment_score": 0.85,
      "reasoning": "The article reports a significant scientific discovery that measuring long-term stress through hair cortisol can predict mental health risks in children with chronic physical illnesses. This finding has broad implications for early identification and intervention, potentially improving mental health outcomes for a large and vulnerable population. The study is detailed, focused, and offers a non-invasive method that could transform preventive care.",
      "category": "Health",
      "personality_title": "Measuring stress in hair helps spot mental health risks in children with chronic illnesses",
      "personality_presentation": "**Context** – Many children with chronic physical illnesses (CPI) face ongoing health challenges that can affect their mental well-being. Around 40% of Canadian children have such illnesses, and they are more likely to develop anxiety, depression, or behavioral problems.\n\n**What happened** – Researchers at the University of Waterloo studied 244 children with CPI over four years. They measured stress by testing cortisol, a hormone that shows long-term stress levels, in hair samples. They found that children with consistently high cortisol were more likely to have mental health difficulties. Those whose cortisol levels dropped over time showed fewer problems.\n\n**Impact** – This discovery is important because hair cortisol tests are easy and painless. They provide a way to identify children who may develop mental health issues early. This means doctors and families could offer help sooner, improving the children’s quality of life and possibly preventing serious emotional struggles.\n\n**What's next step** – Researchers plan to use hair cortisol alongside other tests, like blood markers, to better predict mental health risks. They hope this will lead to regular screening programs for children with chronic illnesses, helping doctors track stress and mental health more closely and tailor treatments effectively.\n\n**One-sentence takeaway** – Testing stress hormones in hair can reveal which children with chronic illnesses are at higher risk for anxiety and depression, allowing earlier support and care.",
      "personality_title_fr": "Mesurer le stress dans les cheveux aide à détecter les risques mentaux chez les enfants malades chroniques",
      "personality_presentation_fr": "**Contexte** – Beaucoup d’enfants atteints de maladies chroniques physiques (MCP) vivent des défis constants qui peuvent affecter leur santé mentale. Environ 40 % des enfants canadiens ont ces maladies et sont plus susceptibles de souffrir d’anxiété, de dépression ou de troubles du comportement.\n\n**Ce qui s’est passé** – Des chercheurs de l’Université de Waterloo ont suivi 244 enfants avec MCP pendant quatre ans. Ils ont mesuré le stress en testant le cortisol, une hormone liée au stress à long terme, dans des échantillons de cheveux. Ils ont découvert que les enfants avec un cortisol élevé de façon persistante avaient plus de problèmes de santé mentale. Ceux dont le cortisol diminuait avaient moins de difficultés.\n\n**Impact** – Cette découverte est importante car le test du cortisol dans les cheveux est simple et sans douleur. Il offre un moyen d’identifier tôt les enfants à risque de troubles mentaux. Cela permettrait aux médecins et familles d’intervenir plus rapidement, améliorant ainsi la qualité de vie des enfants et évitant des difficultés émotionnelles graves.\n\n**Prochaine étape** – Les chercheurs veulent combiner ce test avec d’autres, comme des marqueurs sanguins, pour mieux prédire les risques mentaux. Ils espèrent mettre en place des programmes de dépistage réguliers pour surveiller le stress et adapter les soins aux enfants malades.\n\n**Résumé en une phrase** – Tester le cortisol dans les cheveux peut montrer quels enfants malades chroniques risquent plus d’anxiété et de dépression, permettant un soutien et des soins plus précoces.",
      "personality_title_es": "Medir el estrés en el cabello ayuda a detectar riesgos mentales en niños con enfermedades crónicas",
      "personality_presentation_es": "**Contexto** – Muchos niños con enfermedades físicas crónicas (EFC) enfrentan retos diarios que pueden afectar su salud mental. Alrededor del 40 % de los niños en Canadá tienen estas enfermedades y tienen más probabilidades de sufrir ansiedad, depresión o problemas de comportamiento.\n\n**Qué pasó** – Investigadores de la Universidad de Waterloo estudiaron a 244 niños con EFC durante cuatro años. Midieron el estrés analizando el cortisol, una hormona que indica estrés a largo plazo, en muestras de cabello. Encontraron que los niños con niveles altos de cortisol durante mucho tiempo tenían más problemas de salud mental. Los que mostraron una disminución en el cortisol tuvieron menos dificultades.\n\n**Impacto** – Este hallazgo es importante porque la prueba de cortisol en cabello es fácil y no causa dolor. Permite identificar temprano a los niños que podrían desarrollar problemas mentales. Esto ayuda a que médicos y familias puedan intervenir antes, mejorando la calidad de vida y evitando problemas emocionales graves.\n\n**Próximo paso** – Los investigadores planean usar esta prueba junto con otras, como análisis de sangre, para predecir mejor los riesgos mentales. Quieren crear programas de revisión regular para niños con enfermedades crónicas y así mejorar el seguimiento y tratamiento.\n\n**Resumen en una frase** – Medir el cortisol en el cabello puede mostrar qué niños con enfermedades crónicas tienen mayor riesgo de ansiedad y depresión, permitiendo apoyo y cuidados tempranos.",
      "image_url": "public/images/news_image_Stress-measured-in-hair-could-predict-depression-a.png",
      "image_prompt": "A detailed, warm painting of a gently flowing lock of hair intertwined with delicate, glowing strands resembling cortisol molecules, resting atop a soft, open book symbolizing knowledge and care, set against a calm, natural background with muted earth tones and soft light to evoke hope and early support for children’s mental health."
    }
  ]
}